Radiation Oncologist


Contact Details


Dr. Alexandros Tsikkinis was born and raised in Limassol. He began and completed his medical studies at the University of Heidelberg in Germany. He then went to Bern, Switzerland, where he studied Radiotherapy Oncology and completed his doctoral dissertation. He then continued his postdoctoral research (PostDoc) at the MD Anderson Cancer Center in Houston, USA, and returned to Bern, where he worked for 3 years as a curator (Oberarzt), specializing in breast cancer and gynecological malignancies.

Alexandros always missed his homeland, Cyprus. He visited the island occasionally and waited for the right moment and opportunity to return. When he received the offer to join the Radiotherapy Team at German Oncology Center in Limassol, he didn’t need to think twice. H accepted gladly and in 2019, after 15 fruitful and exciting years of knowledge, research and study abroad, he came home, glad to be able to dedicate himself to helping the people of his island.

More about Alexandros Tsikkinis


  • Professional Experience
  • Research Fellowship
  • Doctorate Degree
  • Medical Education
  • Professional Development
  • Memberships in Scientific Societies
  • Publications
  • 2019: German Oncology Center; Limassol, Cyprus
    Consultant Radiation Oncology
  • 2012 – 2014: University Clinic for Radiation Oncology; Inselspital Bern, Switzerland
  • 2015 – 2016: Consultant Radiation Oncology (Breast & Gynecological Tumors)
  • 2017 – 2019: University Clinic for Internal Medicine; Inselspital Bern, Switzerland
  • 2014 – 2015: Clinical Oncology Ward
  • 2017: Board Certification Exam in Radiation Oncology

2016 – 2017: Department of Genitourinary Oncology
David H. Koch Center for applied research of genitourinary cancers
MD Anderson Cancer Center; Houston, USA

2015: Faculty of Medicine, University of Bern, Switzerland

  • 2005 – 2011: Studies of Medicine at the Ruprecht-Karls-University Heidelberg, Germany
  • 2011 – 2012: Practical Year (Training Electives)
  • 2012: Final State Examination (Staatsexamen)
  • 05/2015: Radiation Protection Course, SRO (Kantonsspital Aarau, Switzerland)
  • 10/2015: Physics Course, SRO (Paul Scherrer Institute Villigen, Switzerland)
  • 10/2015: SAKK Investigators’ Education (Good Clinical Practice) Course (Bern, Switzerland)
  • 11/2015: ESTRO Course: IGRT and chemotherapy in gynaecological cancer,
  • 03/2016: focus on adaptive brachytherapy (UMC Utrecht, Netherlands)
    ESTRO Course: Modern Brachytherapy Techniques (University of Florence, Italy)
  • 08/2016: North and South American Prostate Cancer Symposium (Houston, USA)
  • 01/2017: Mechanisms of Castration Resistance & Metastasis in Prostate Cancer
    Prostate Cancer Moon Shot Symposium (Houston, USA)
  • Since 2017: GEC-ESTRO yearly Brachytherapy Workshops
  • Since 2014: ASCO (American Society of Clinical Oncology)
  • Since 2014: SASRO (Scientific Association of Swiss Radiation Oncology)
  • Since 2015: ESTRO (European Society for Radiotherapy and Oncology)
  • Since 2016: ASTRO (American Society for Radiation Oncology)
  • Since 2016: ESMO (European Society for Medical Oncology)
Reviewing Work for Peer – Reviewed Journals
  • Since 2015: Radiation Oncology (www.RO-Journal.com)
  • Since 2017: OncoTargets and Therapy (www.dovepress.com)
  • Since 2018: BMC Cancer (https//bmccancer.biomedcentral.com)
Peer – Reviewed Publications
  • In Print: A candidate androgen signaling signature predictive of response to Abiraterone acetate in men with metastatic castration resistant prostate cancer. Tsikkinis A., Efstathiou E., et al
    http://dx.doi.org/xxx (European Journal of Cancer)
  • 04/2019: Breast Cancer Care in Northern Ethiopia – Planning for a Better Future
    Deressa B., Tsikkinis A., Rauch D., et al
    http://dx.doi.org/10.1186/s12885-019-5612-6 (BMC Cancer)
  • 02/2019: Dosimetric Analysis of the InCise 2 Multi Leaf Collimator and IRIS-Based
    Stereotactic Radiotherapy Plans for Brain and Liver Tumors
    https://doi.org/10.1088/2057-1976/ab0beb (Biomed. Phys. Eng. Express)
  • 05/2018: Clinical trials involving positron emission tomography and prostate cancer: An analysis of the ClinicalTrials.gov database
    Cihoric N., Vlaskou BE, Tsikkinis A., Ghadjar P. et al
    http://dx.doi.org/10.1186/s13014-018-1057-3 (Radiation Oncology Journal)
  • 08/2017: Highly conformal combined radiotherapy with cisplatin and gemcitabine for the treatment of loco-regionally advanced cervical cancer
    Cihoric N., Tsikkinis A., Aebersold D., Lössl K. et al
    https://doi.org/10.1186/s13014-017-0938-1 (Radiation Oncology Journal)
  • 12/2016: Current status and perspectives of interventional clinical trials for Glioblastoma – analysis of ClinicalTrials.gov Tsikkinis A., Cihoric N., Niyazi M. et al
    http://dx.doi.org/10.1186/s13014-016-0740-5 (Radiation Oncology Journal)
  • 03/2016: Portfolio of prospective clinical trials including brachytherapy; An analysis of the ClinicalTrials.gov database.
    Tsikkinis A., Cihoric N., Aebersold D., Ghadjar P., Lössl K. et al
    http://dx.doi.org/10.1186/s13014-016-0624-8 (Radiation Oncology Journal)
  • 11/2015: Dose escalated IMRT in the treatment of cervical cancer patients Cihoric N., Tsikkinis A., Tapia C., Aebersold D., Lössl K. et al
    http://dx.doi.org/10.1186/s13014-015-0551-0 (Radiation Oncology Journal)
  • 06/2015: Clinical perspectives from Randomized Phase 3 trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database
    Tsikkinis A., Cihoric N., Aebersold D., Ghadjar P. et al
    http://dx.doi.org/10.1016/j.euf.2015.05.003 (European Urology Focus)
  • 05/2015: Hyperthermia-related clinical trials on cancer treatment within the ClinicalTrials.gov registry
    Cihoric N., Tsikkinis A., Aebersold D., Ghadjar P. et al
    http://dx.doi.org/10.3109/02656736.2015.1040471 (International Journal of Hyperthermia)
Submitted Publications (Under Review)
  • Under Review: State of the art treatment options in the management of prostate cancer.
    Current trends and upcoming treatment options.
  • Under Review: Clinical factors associated with the recurrence of operated nonfunctioning pituitary adenomas: a study on 203 patients.
Letters to the Editor
  • 12/2018: A step forward in cancer informatics – it is mandatory to make guidelines machine readable
    Cihoric N., Igrutinovic I., Tsikkinis A.
    http://dx.doi.org/10.5166/jroi-9-1-1 (Journal of Radiation Oncology Informatics)
  • 02/2016: Treatment options for isolated loco regional recurrences of NSCLC after surgery. Yes, Radiation Therapy, Too!
    Cihoric N., Tsikkinis A., Filipovic N., Jeremic B.
    http://dx.doi.org/10.1183/13993003.00388-2016 (European Respiratory Journal)
Invited Articles
  • 12/2015: Analysis of clinical trials in Radiation Oncology: A characterization of the ClinicalTrials.gov Database
    Tsikkinis A., Cihoric N., Aebersold D., Zaugg K.
    (Schweizer Krebsbulletin; Issue 35, December 2015)
  • 11/2018: A Gentle Introduction to Dictionaries, Terminologies, Classifications, Thesauruses, Ontologies and other Lexical Resources in Oncology Research – A mini review – Cihoric N., Vlaskou BE, Aebersold D., Tsikkinis A.
  • SASRO 19: Benefits of an additional MRI for adaptive HDR-brachytherapy in gynaecological cancers
  • ESTRO 19: Multi-institutional treatment and management of cervical cancer patients
  • ESTRO 19: Observational study on partial breast irradiation conducted with interstitial multicatheter HDR brachytherapy for breast cancer after breast conserving surgery.
  • ESTRO 19: The role of 18FDG -PET/CT in treatment response assessment and follow-up of cervical cancer after definitive radio/chemotherapy
  • SASRO 18: Multi-institutional treatment of patients with cervical cancer in Switzerland
  • SASRO 18: Value of 18F-FDG PET/CT in the follow up of cervical cancer patients
  • UROK 18: Plan comparison of IRIS based and InCise 2 Multileaf Collimator based Radiosurgery for brain and liver Tumors
  • ESTRO 18: Clinical trials in 15 malignancies with the highest mortality rate on a global scale.
  • ASTRO 17: Cisplatin and gemcitabine combined with highly conformal external beam radiation therapy in the treatment of cervical cancer patients results in low toxicity and promising outcome
    http://dx.doi.org/10.1016/j.ijrobp.2017.06.1288 (Red Journal)
  • ESMO 16: Abiraterone acetate followed by randomization to Dasatinib or Sunitinib malate in metastatic castrate resistant prostate cancer (mCRPC)
    http://dx.doi.org/10.1093/annonc/mdw372.11 (Annals of Oncology)
  • ASTRO 16: Bladder-Preserving Combined-Modality Therapy: What is Coming Next? A Critical Analysis of Phase 2-3 Trials of the ClinicalTrials.gov Database
    http://dx.doi.org/10.1016/j.ijrobp.2016.06.1335 (Red Journal)
  • ASCO 16: Neoadjuvant Enzalutamide and Abiraterone acetate plus leuprolide acetate (LHRHa) versus AA+ LHRHa in localized high-risk prostate cancer
  • SGC 16: Contemporary surgical phase III clinical trials investigating colorectal carcinoma. An Analysis of the ClinicalTrials.gov database
  • SASRO 15: Portfolio of prospective clinical trials including brachytherapy; An analysis of the ClinicalTrials.gov database
  • ESHO 15: Inventory of hyperthermia related clinical trials as registered in ClinicalTrials.gov
  • ASTRO 14: A comprehensive analysis of the ClinicalTrials.gov database; Focus on radiation oncology
    http://dx.doi.org/10.1016%2Fj.ijrobp.2014.05.1750 (Red Journal)
  • SASRO 14: VMAT Radiotherapy with concomitant cisplatin and gemcitabine for the treatment of loco-regionally advanced cervical cancer
  • SASRO 14: Landscape of radiation-oncology clinical trials in gynaecological malignancies: a comprehensive analysis of the ClinicalTrials.gov database
Unpublished Work
  • Manuscript Abiraterone acetate and dasatinib or sunitinib in men with metastatic castration-Preparation resistant prostate cancer progressing on Abiraterone acetate alone (2010-0070): a randomised phase 2 trial. Tsikkinis A., Efstathiou E., Logothetis C. et al
  • Manuscript Perspectives in the Treatment of Bladder Cancer: A Critical Analysis of the Next Preparation Phase II and III Trials of the ClinicalTrials.gov Database

© German Oncology Center. All rights reserved.